| Literature DB >> 20430443 |
Dong-Wook Kim1, Shripad D Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, He Huang, Ian Irving, Saengsuree Jootar, Hyun-Gyung Goh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman, Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, Jianmin Wang, Raymond Wong.
Abstract
Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization. Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20430443 DOI： 10.1016/j.leukres.2010.03.033
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156